Originally dba Argus Pharmacueticals, in 1995 the firm acquired Oncologix, Inc.and Triplex Pharmaceutical Corporation (also SBIR involved) and became Aronex Pharmaceuticals, Inc. Engaged in the identification and development of proprietary innovative medicines to treat cancer and infectious diseases, With efforts devoted substantially to research and product development, the Company's infectious disease program currently focuses on the development of Nyotran(r) for life-threatening systemic, or internal, fungal infections and Zintevir(r) for the treatment of HIV infection. Its cancer program focuses on development of Atragen(r) for hematological malignancies and solid tumors, and Annamycin for breast cancer. Also underdevelopment was the novel platinum analogue, Platar, for the treatment of solid tumors, and AR209, an innovative cancer therapy that has potential for additional solid tumor indications, including lung, ovarian and stomach cancers. In April 2001 Antigenics Inc. (Nasdaq: AGEN) announced that it would acquire Aronex Pharmaceuticals Inc (Nasdaq: ARNX) . for approximatly $30 million in a stock for stock deal.
